NVO Novo Nordisk AS: Enterprise Value-to-Revenue Multiple

Official company branding of Novo Nordisk (NVO)

Dominance in the GLP-1 segment and patent protection allow Novo Nordisk A/S (NVO) to maintain pricing power, driving growth in the enterprise value-to-revenue ratio. Global expansion of production capacities and its leadership status in diabetes therapy ensure ultra-high margins and a stable cash cow. The value of 2696.33 reflects the metric's balance, helping to isolate the fundamental trend from market noise.

Novo Nordisk (NVO) - Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/21/2026

NVO (Novo Nordisk A/S): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:NVO, novonordisk.com
Product sample of Novo Nordisk Group

Novo Nordisk A/S (NVO) revenue is based on global sales of innovative drugs for diabetes, obesity, and rare blood clotting disorders. This revenue stream is compared against the total enterprise value minus net debt, which eliminates the impact of leverage on the valuation. By analyzing the EV-to-revenue trend, an investor determines the degree of overvaluation of the asset or the potential for price growth.